Autoimmune and Autoinflammatory Pericarditis: Definitions and New Treatments.
Emanuele BizziLucia TrottaMassimo PancraziMariangela NivuoriValeria GiosiaLuca MatteucciDaniela MontoriAntonio BrucatoPublished in: Current cardiology reports (2021)
Several studies have been published on the use of anti-IL-1 drugs in recurrent pericarditis, including anakinra and rilonacept. The latest, the RHAPSODY study, based on the use of rilonacept in recurrent pericarditis, has recently reached phase 3 with promising results in terms of efficacy and safety. Alterations in the function of the inflammasome and the consequent overproduction of IL-1 play a pivotal role in the genesis of autoinflammatory pericarditis. Recent studies added evidence to the importance of anti-IL-1 drugs in the treatment of recurrent pericarditis with raised C-reactive protein. In the era of tailored medicine, anti-IL-1 agents may be very useful in the subset of patients with recurrent pericarditis and a clear inflammatory phenotype.